ebrahim hosseini

Dr. ebrahim hosseini


Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 December 2018 in Journal of Psychiatric Research
Verified
Journal Article
Closed access
FZFatemeh Zadehbagheri
Fatemeh Zadehbagheri
EHebrahim hosseini
ebrahim hosseini
ZBZahra Bagheri-Hosseinabadi
Zahra Bagheri-Hosseinabadi
HRHossein Moradi Rekabdarkolaee
Hossein Moradi Rekabdarkolaee
ISIman Sadeghi
Iman Sadeghi

13 October 2023 in Naunyn-Schmiedeberg's Archives of Pharmacology
Verified
Journal Article
Closed access
PDF file
FKFatemeh Khosravani
Fatemeh Khosravani
FAFatemeh Amiri
Fatemeh Amiri
RMRouzbeh Mahmoudi
Rouzbeh Mahmoudi
DMDina Morshedi
Dina Morshedi
FKFarzad Kobarfard
Farzad Kobarfard
HBHassan Bardania
Hassan Bardania

13 May 2022 in Molecular Biology Reports
Verified
Journal Article
Closed access
PDF file
SHSara Hosseinpor
Sara Hosseinpor
BKBahman Khalvati
Bahman Khalvati
FSFarahad Safari
Farahad Safari
AMAli Mirzaei
Ali Mirzaei
EHebrahim hosseini
ebrahim hosseini

19 October 2024 in Molecular Neurobiology
Verified
Journal Article
Closed access
PDF file
AGAmir Ghanbari
Amir Ghanbari
PFParisa Danaie Fard
Parisa Danaie Fard
NANahid Azarmehr
Nahid Azarmehr
RMReza Mahmoudi
Reza Mahmoudi
ARAmrollah Roozbehi
Amrollah Roozbehi
EHebrahim hosseini
ebrahim hosseini

3 April 2019 in Journal of Chemotherapy
Verified
Journal Article
Closed access
AGAmir Ghanbari
Amir Ghanbari
ZCZeinab Cheraghzadeh
Zeinab Cheraghzadeh
RMReza Mahmoudi
Reza Mahmoudi
KZKazem Zibara
Kazem Zibara
EHebrahim hosseini
ebrahim hosseini
Inhibition of hedgehog (Hh) signalling pathway, including its end effector GLI1, can reverse epithelial-to-mesenchymal transition (EMT) which plays an important role in drug resistance of pancreatic cancer cells to Erlotinib (ETB). This study investigated the effect of GLI inhibitors Forskolin (FSK), GANT-61 (GNT), and Arsenic trioxide (ATX) on suppressing the resistance of pancreatic cancer cells to ETB. The effect of GLI inhibitors was evaluated by measuring mRNA expression levels of EMT factors using quantitative RT-PCR. Immunocytochemistry and flow cytometry were used to assess E-cadherin (E-Cad) and GLI1 protein levels. MTT and apoptosis assays were used to evaluate the synergistic effects for the combination treatment of each GLI inhibitor with ETB. Pancreatic cancer cells PANC-1 treated by GNT showed the highest significant reduction in mRNA levels of GLI1 and other EMT pathway genes. Moreover, GNT was able to upregulate E-Cad and downregulate GLI1 proteins, more than FSK, while ATX had no effect. Apoptosis levels of PANC-1 cells following treatment with LD30 concentrations of FSK, GNT, or ATX, showed 57%, 62% and 67%, respectively, in comparison to ETB (∼48%). Importantly, combination treatments of ETB with either FSK, GNT, or ATX demonstrated a significant increase in apoptotic cells reaching 61% (ETB + FSK), 80% (ETB + GNT) or 88% (ETB + ATX). FSK did not have much effect on the drug resistance of PANC-1 cells to ETB. However, GNT, but more effectively ATX, were able to reduce the drug resistance of this cell line to ETB.